SILVER SPRING
Filspari approved for focal segmental glomerulosclerosis
- Sponsor
- Travere Therapeutics $TVTX
- Drug
- Filspari · sparsentan
- Indication
- focal segmental glomerulosclerosis
FDA approved Filspari (sparsentan) to reduce proteinuria in adult and pediatric patients with focal segmental glomerulosclerosis.
What this means
Filspari is an oral medication that blocks two key proteins involved in kidney damage, helping reduce protein loss in urine. FDA approved Filspari for treating focal segmental glomerulosclerosis, a rare kidney disease, in both adults and children. This decision gives patients with this condition a new treatment option that may help slow kidney damage and improve outcomes.